



Fycompa[®] (perampanel) – Expanded indication

- On July 26, 2017, [Eisai announced](#) the FDA approval of [Fycompa \(perampanel\)](#) as monotherapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
 - Previously, Fycompa was only approved for use as adjunctive therapy in partial-onset seizures.
 - Fycompa is also approved as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
- Fycompa's approval for monotherapy use was extrapolated based on comparable exposures to those obtained with adjunctive use in clinical trials for the treatment of partial-onset seizures.
- Fycompa carries a boxed warning for serious psychiatric and behavioral reactions.
- The recommended starting dose of Fycompa for monotherapy or adjunctive therapy for partial onset seizures is 2 mg once daily taken orally at bedtime.
 - The dose may be increased by increments of 2 mg once daily based on individual clinical response and tolerability, no more frequently than at weekly intervals.
 - The recommended maintenance dose range is 8 mg to 12 mg once daily, although some patients may respond to a dose of 4 mg daily.
 - Refer to the prescribing information for dosing recommendations for tonic-clonic seizures.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.